August 31, 2020August 31, 2020

Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC

News

The Canadian Cancer Trials Group (CCTG) has launched a Phase 2 study of CFI-400945 in combination with Imfinzi (durvalumab) for the treatment of advanced or metastatic triple negative breast cancer (TNBC). ... Read more

July 6, 2018July 6, 2018

Imfinzi-Chemo Combo Shows Effectiveness in Treating Triple-negative Breast Cancer, Phase 2 Study Shows

News

The combination of Imfinzi (durvalumab) with standard chemotherapy leads to high treatment effectiveness in patients with triple-negative breast cancer (TNBC), a Phase 2 trial shows. The research, “Randomized phase II ... Read more